Literature DB >> 1486161

Short report: omeprazole plus antibiotic combinations for the eradication of metronidazole-resistant Helicobacter pylori.

G D Bell1, K U Powell, S M Burridge, G Spencer, G Bolton, K Purser, S Brooks, S Prosser, G Harrison, P W Gant.   

Abstract

Twenty-eight Helicobacter pylori-positive patients with metronidazole-resistant isolates and 25 with metronidazole-sensitive isolates were treated for 14 days with 40 mg omeprazole nocte plus 500 mg amoxycillin t.d.s. Eradication of H. pylori, defined as absence of the organism one month after cessation of treatment, was assessed using the [14C]urea breath test. The eradication rate in patients with metronidazole-resistant isolates was 14/28 (50%) while that in patients was metronidazole-sensitive isolates was 12/25 (48%). In contrast to these encouraging eradication rates, very poor results were obtained with a 7-day course of omeprazole (40 mg nocte) in combination with erythromycin ethylsuccinate (500 mg q.d.s.) and tripotassium dicitrato bismuthate tablets (120 mg q.d.s.). The latter eradication rates were 3/20 (15%) in patients taking erythromycin tablets and 3/19 (16%) in those taking a liquid formulation of erythromycin. All treatment regimens were well tolerated and all patients completed the prescribed course of therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1486161     DOI: 10.1111/j.1365-2036.1992.tb00740.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  13 in total

1.  Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin.

Authors:  A M Craig; P Davey; M Malek; F Murray
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

Review 2.  Hyperplastic proliferations of enteroendocrine cells.

Authors:  Yogeshwar Dayal
Journal:  Endocr Pathol       Date:  1994-03       Impact factor: 3.943

Review 3.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

4.  Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong.

Authors:  C K Ching; K P Leung; R W Yung; S K Lam; B C Wong; K C Lai; C L Lai
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

5.  Comparison of PCR-based restriction length polymorphism analysis of urease genes with rRNA gene profiling for monitoring Helicobacter pylori infections in patients on triple therapy.

Authors:  R J Owen; J Bickley; A Hurtado; A Fraser; R E Pounder
Journal:  J Clin Microbiol       Date:  1994-05       Impact factor: 5.948

6.  Effect of omeprazole on movement of intravenously administered metronidazole into gastric juice and its significance in treatment of Helicobacter pylori.

Authors:  S J Veldhuyzen van Zanten; P T Pollak; H Kapoor; P K Yeung
Journal:  Dig Dis Sci       Date:  1996-09       Impact factor: 3.199

7.  Detection of the intragastric sites at which Helicobacter pylori evades treatment with amoxycillin and cimetidine.

Authors:  J C Atherton; A Cockayne; M Balsitis; G E Kirk; C J Hawkey; R C Spiller
Journal:  Gut       Date:  1995-05       Impact factor: 23.059

8.  Mucoadhesive microspheres containing amoxicillin for clearance of Helicobacter pylori.

Authors:  N Nagahara; Y Akiyama; M Nakao; M Tada; M Kitano; Y Ogawa
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

9.  The role of screening for Helicobacter pylori in patients with duodenal ulceration in the primary health care setting.

Authors:  H Rosengren; R J Polson
Journal:  Br J Gen Pract       Date:  1996-03       Impact factor: 5.386

10.  Current guidelines for the eradication of Helicobacter pylori in peptic ulcer disease.

Authors:  E A Rauws; R W van der Hulst
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.